(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 June 2023 (29.06.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/115142 A1

(51) International Patent Classification:
C07D 471/04 (2006.01) *C07D 519/00* (2006.01)
C07D 487/04 (2006.01) *A61P 35/00* (2006.01)
C07D 491/048 (2006.01)

(21) International Application Number:
PCT/AU2022/051568

(22) International Filing Date:
22 December 2022 (22.12.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2021904206 22 December 2021 (22.12.2021) AU

(71) Applicant: **ANAXIS PHARMA PTY LTD** [AU/AU]; Bio21 Institute, 30 Flemington Road, Parkville, Victoria 3052 (AU).

(72) Inventors: **BRZOZOWSKI, Martin**; c/- Bio21 Institute, 30 Flemington Road, Parkville, Victoria 3052 (AU). **POITEVIN, Christophe**; c/- Bio21 Institute, 30 Flemington Road, Parkville, Victoria 3052 (AU). **GARNIER, Jean-Marc Daniel**; c/- Bio21 Institute, 30 Flemington Road, Parkville, Victoria 3052 (AU). **GARDNER, Christopher**; c/- Bio21 Institute, 30 Flemington Road, Parkville, Victoria 3052 (AU). **LESSENE, Guillaume Laurent**; c/- Bio21 Institute, 30 Flemington Road, Parkville, Victoria 3052 (AU). **CZABOTAR, Peter Edward**; c/- Bio21 Institute, 30 Flemington Road, Parkville, Victoria 3052 (AU). **SCHUSTER-KLEIN, Carole Annie**; c/- Bio21 Institute, 30 Flemington Road, Parkville, Victoria 3052 (AU). **DAVIES, Katherine**; c/- Bio21 Institute, 30 Flemington Road, Parkville, Victoria 3052 (AU). **COWAN, Angus**; c/- Bio21 Institute, 30 Flemington Road, Parkville, Victoria 3052 (AU). **KERSTEN, Wilco**; c/- Bio21 Institute, 30 Flemington Road, Parkville, Victoria 3052 (AU).

(74) Agent: **FPA PATENT ATTORNEYS PTY LTD**; Level 19, South Tower, 80 Collins Street, Melbourne, Victoria 3000 (AU).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

WO 2023/115142 A1

(54) Title: ARYLSULPHONAMIDE COMPOUNDS



(I)

(57) Abstract: This invention relates to compounds of formula (I) and salts, solvates, tautomers, N-oxides, stereoisomers, polymorphs and/or prodrugs thereof. Also disclosed is the use of the compounds of formula (I) to treat necroptosis and/or inhibit MLKL.